High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma

Wang, Hua; Wang, Liang; Dong, Pei liang; Wang, Wei Da; Chen, Xiao Qin; Geng, Qi Rong; Xia, Zhong Jun; Lu, Yue

doi:10.1038/bjc.2016.11

Cited by 61 publications

(61 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognosis of MM patients was influenced by IL‐10. Wang et al demonstrated that the MM patients with high serum level of IL‐10 had shorter OS and progression‐free survival than those with low serum level of IL‐10 . Likewise, the IL‐10 −592 CA and CC (high‐producer type) genotypes were significantly associated with poor survival in the present study.…”

Section: Discussionsupporting

confidence: 68%

“…In this study, there was no significant difference in IL‐10 and IL‐10R polymorphisms between the control group and the MM group, and these results suggested that the IL‐10 and IL‐10R polymorphisms are not implicated in the susceptibility to MM of the Japanese. Some investigators have suggested that a high serum level of IL‐10 is correlated to a high stage of disease according to the ISS and the Durie and Salmon classification . A high level of IL‐10 has also been demonstrated in the serum of MM patients with light chain disease and renal failure .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Polymorphism of IL‐10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib

Kasamatsu

Saitoh

Ino

et al. 2016

Hematological Oncology

View full text Add to dashboard Cite

Interleukin-10 (IL-10) and IL-10 receptor (IL-10R) single nucleotide polymorphisms have been implicated in the pathogenesis of many cancers. We investigated the influence of IL-10 -592C/A, IL-10RA I224V, and IL-10RB K47E on the risk of developing multiple myeloma (MM) and the clinical features of MM. We extracted the genomic DNA from 128 MM patients and 202 healthy controls and used polymerase chain reaction-restriction fragment length polymorphism method to detect IL-10 promoter -592C/A (rs1800872), IL-10RA (rs2228055), and IL-10RB K47E (rs2834167) genotypes. Overall survival (OS) was defined as the interval from the date of diagnosis to the date of death or last clinical appointment. No statistically significant difference was observed in the genotype and allele frequencies of IL-10 -592C/A, IL-10RA I224V, and IL-10RB K47E between MM patients and healthy controls. IL-10RA II genotype was significantly associated with a hemoglobin level lower than that of IV and VV genotypes (mean ± standard deviation, 9.21 ± 2.46 vs 10.3 ± 2.33 g/dL; P = .021). IL-10 -592 AA genotype was significantly associated with OS better than that of CA and CC genotypes (median OS, 74.5 vs 46.3 months; P = .047). We observed significant differences in survival between patients treated with thalidomide and/or bortezomib and those treated with conventional treatments (median OS, 74.5 vs 38.2 months; P = .021). Therefore, we also examined the effect of IL-10 and IL-10R polymorphisms on the clinical variables and OS of patients treated with thalidomide and/or bortezomib. In addition, IL-10RB EE genotype was significantly associated with poorer survival than KK and KE genotypes (median OS, 46.3 vs 78.8 months; P = .015). Our findings indicate that IL-10 and IL-10R gene polymorphisms may not contribute to the susceptibility to MM but may be associated with the severity and prognosis of MM. In particular, IL-10RB K47E polymorphism may contribute to the poor prognosis of MM patients treated with thalidomide and/or bortezomib.

show abstract

Section: Discussionsupporting

confidence: 68%

Section: Discussionmentioning

confidence: 99%

Polymorphism of IL‐10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib

Kasamatsu

Saitoh

Ino

et al. 2016

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Subjects in the low IL-10 group had superior survival compared with those in the high IL-10 group (3-year PFS rate: 69.3% versus 13.3%; 3-year OS rate: 93.6% versus 51.9%). Multivariate analysis confirmed that high serum IL-10 concentrations at diagnosis was an unfavourable factor for PFS and OS [ 210 ].…”

Section: Anti-inflammatory Cytokinesmentioning

confidence: 96%

Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma

Musolino

Allegra

Innao

et al. 2017

Mediators of Inflammation

118

113

View full text Add to dashboard Cite

Multiple myeloma (MM) is typically exemplified by a desynchronized cytokine system with increased levels of inflammatory cytokines. We focused on the contrast between inflammatory and anti-inflammatory systems by assessing the role of cytokines and their influence on MM. The aim of this review is to summarize the available information to date concerning this equilibrium to provide an overview of the research exploring the roles of serum cytokines in MM. However, the association between MM and inflammatory cytokines appears to be inadequate, and other functions, such as pro-proliferative or antiproliferative effects, can assume the role of cytokines in the genesis and progression of MM. It is possible that inflammation, when guided by cancer-specific Th1 cells, may inhibit tumour onset and progression. In a Th1 microenvironment, proinflammatory cytokines (e.g., IL-6 and IL-1) may contribute to tumour eradication by attracting leucocytes from the circulation and by increasing CD4 + T cell activity. Hence, caution should be used when considering therapies that target factors with pro-or anti-inflammatory activity. Drugs that may reduce the tumour-suppressive Th1-driven inflammatory immune response should be avoided. A better understanding of the relationship between inflammation and myeloma will ensure more effective therapeutic interventions.

show abstract

“…19 The survival time in various hematologic malignancies and ovarian cancer has been reported to be negatively correlated with the levels of IL-10. 20,21 In ALS, the role of IL-10 has only been studied in a small cohort. One previous retrospective study of 29 patients found that higher plasma IL- Abbreviations: ALS = amyotrophic lateral sclerosis; HR = hazard ratio; IFN-α = interferon alpha; IL = interleukin; NA = not applicable; n analyzed = number of patient samples analyzed; n LLOD = number of samples in this analysis with cytokine levels below lower limit of detection; OMND = other motor neuron disease; TNF-α = tumor necrosis factor alpha; TRAIL = TNF-related apoptosis-inducing ligand.…”

Section: Immunopathologic Processes Related To Als Genetic Variantsmentioning

confidence: 99%

Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis

Olesen

Wuolikainen

Nilsson

et al. 2020

Neurol Neuroimmunol Neuroinflamm

View full text Add to dashboard Cite

ObjectiveTo investigate inflammatory cytokines in patients with motor neuron disease (MND) evaluating the putative contribution of amyotrophic lateral sclerosis (ALS)-causing gene variants. MethodsThis study is a retrospective case series with prospective follow-up (1994-2016) of 248 patients with MND, of whom 164 had ALS who were screened for mutations in the genes for SOD1 and C9orf72. Paired CSF and plasma were collected at the diagnostic evaluation before treatment. A panel of cytokines were measured blindly via digital ELISA on the Simoa platform. ResultsTime from disease onset to death was longer for patients with ALS-causing SOD1 mutations (mSOD1, n = 24) than those with C9orf72 hexanucleotide repeat expansion (C9orf72HRE) ALS (n = 19; q = 0.001) and other ALS (OALS) (n = 119; q = 0.0008). Patients with OALS had higher CSF tumor necrosis factor alpha (TNF-α) compared with those with C9orf72HRE ALS (q = 0.014). Patients with C9orf72HRE ALS had higher CSF interferon alpha compared with those with OALS and mSOD1 ALS (q = 0.042 and q = 0.042). In patients with ALS, the survival was negatively correlated with plasma interleukin (IL) 10 (hazard ratio [HR] 1.17, 95% CI 1.05-1.30). Plasma TNF-α, IL-10, and TNF-related apoptosis-inducing ligand (TRAIL) (HR 1.01 [1.00-1.02], 1.15 [1.02-1.30], and 1.01 [1.00-1.01], respectively) of patients with OALS, plasma IL-1β .5]) of patients with C9orf72HRE ALS, and CSF TRAIL (10.5 [1.12-98.6]) of patients with mSOD1 ALS all correlated negatively with survival. ConclusionsDifferences in survival times in ALS subtypes were correlated with cytokine levels, suggesting specific immune responses related to ALS genetic variants. Glossary ALS = amyotrophic lateral sclerosis; dsRNA = double-stranded RNA; FTD = frontotemporal dementia; HR = hazard ratio; HRE = hexanucleotide repeat expansion; IFN = interferon; IFN-α = interferon alpha; IL = interleukin; IVIg = IV immunoglobulin; MND = motor neuron disease; OALS = other amyotrophic lateral sclerosis; OMND = other motor neuron diseases; PBP = progressive bulbar palsy; TNF = tumor necrosis factor; TNF-α = tumor necrosis factor alpha; TRAIL = TNFrelated apoptosis-inducing ligand.

show abstract

High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma

Cited by 61 publications

References 33 publications

Polymorphism of IL‐10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib

Polymorphism of IL‐10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib

Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma

Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis

Contact Info

Product

Resources

About